Top Pharmaceutical Companies in San Diego, CA (124)
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Growth across non‑COVID medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars has been robust. Launched and acquired products are showing sustained double‑digit operational gains, adding meaningful momentum.
Resilient & Sustainable Growth: Excluding COVID products, the underlying portfolio delivered mid‑single‑digit operational growth in 2025 and continued at a similar pace in early 2026, more than offsetting part of the COVID‑related decline. Reported revenue also returned to modest year‑over‑year growth in the first half of 2026, indicating stabilization.
Future-Ready Strategy: Management raised the midpoint of 2026 revenue guidance and continues to invest heavily in a broad late‑stage pipeline. This posture signals confidence that newer launches and acquired assets can drive the next leg of growth.
Trialfacts was established in 2006 to provide specialised patient recruitment services and effective solutions to the clinical trial industry. Trialfacts combines it’s extensive marketing and advertising expertise with in-depth clinical trial experience to create effective marketing solutions that adhere to GCP and HREC requirements. If you’d like to learn more please visit https://trialfacts.com/participantsguaranteed
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
From 1986 to 2020 we operated as Robarts Clinical Trials and built a strong foundation in the medical research community. In 2020, we became Alimentiv but retained our commitment to clinical trials, medical imaging, and precision medicine for GI-related ailments.
Our Acadia family of care-ageous warriors aspire to enable brighter moments for patients and their loved ones. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the...
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than...
Ferring Pharmaceuticals's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 revenues exceeded €2.5 billion, rising versus 2024 with notable momentum in the U.S. and key contributions from Menopur and Adstiladrin. Company disclosures and the annual report indicate continued year-over-year top-line expansion.
Innovation-Driven Growth: First-in-class approvals (Rebyota in microbiome therapeutics and Adstiladrin in bladder-cancer gene therapy) and WHO-recognized maternal-health innovation (heat-stable carbetocin) demonstrate differentiated science translating into commercial progress. FDA clearance of a second U.S. Adstiladrin site supports scaling these innovations.
Strong Market Position & Advantage: Leadership in ART/fertility and first-mover status in microbiome therapeutics and intravesical gene therapy provide competitive advantages in defined niches. This positioning underpins recent growth in core franchises.
PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market. With facilities in North America and Europe, PCI supports pharmaceutical and biotech companies with products destined for more than 100 countries around the world. PCI provides services for each stage of the product lifecycle – from early Phase I through commercial launch and long-term supply...
PCI Pharma Services's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Feedback suggests PCI secured a major 2025 strategic investment alongside existing owners at a multi‑billion valuation to accelerate organic and inorganic growth. Multiple disclosures highlight hundreds of millions committed to U.S. and EU capacity and M&A adding sterile fill‑finish and high‑potent capabilities.
Strong Market Position & Advantage: Feedback suggests PCI is widely regarded as a leader in clinical‑trial supply, advanced packaging/drug‑device assembly, and an expanding sterile fill‑finish/lyo footprint, supporting thousands of development programs and a meaningful share of top marketed drugs. Awards and frequent product launches are cited as reinforcing quality and reliability at scale.
Market Expansion: Feedback suggests PCI is in a clear expansion phase with large build‑outs in Rockford, IL and Dublin, Ireland, and added U.S. sterile presence via acquisition in San Diego. New and upgraded sites (e.g., Bedford, NH with lyophilization and isolator‑based lines) broaden capacity in injectables and prefilled formats with go‑live targets through 2025.
Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.
Technical Safety Services is a leading provider of testing, inspection, certification, and calibration (TICC) services, specializing in controlled environments such as cleanrooms, fume hoods, and biosafety cabinets. The company serves highly regulated industries, including biotechnology, pharmaceuticals, aerospace, medical devices, and healthcare, ensuring compliance for laboratories, hospitals, and pharmacies.
Condor Software is a financial intelligence platform that provides an automated financial cloud specifically for accounting, finance, and clinical operations teams in the biopharmaceutical industry. The company's AI-driven infrastructure integrates clinical, operational, and financial data to streamline R&D spending, budgeting, forecasting, and scenario planning, helping biopharma organizations accelerate the delivery of life-changing therapies to patients by replacing fragmented, manual processes...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give...
Jazz Pharmaceuticals, Inc's Top Stability & Growth Strengths
Strong Market Position & Advantage: Jazz is described as a clear leader in rare sleep disorders through its oxybate franchise (Xywav/Xyrem and authorized generics royalties) and in cannabinoid-based epilepsy with Epidiolex surpassing $1B in 2025. Xywav’s idiopathic hypersomnia approval with orphan exclusivity and category-leading revenue reinforce defensibility.
Strong Revenue Growth: Record 2025 revenue around $4.27 billion and a record Q4, with 2026 guidance still pointing up, indicate sustained top-line momentum. Company communications highlight a multi-year streak of annual growth continuing into 2026.
Diversified Revenue Streams: A balanced base with rare sleep revenues above $2B, Epidiolex above $1B, and roughly $1.13B in oncology plus new contributions from Modeyso and royalties shows multiple revenue pillars. Pipeline drivers like zanidatamab and Zepzelca label expansion add additional avenues.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product...
MedImpact, an independent, trend-focused pharmacy benefit manager (PBM), is the nation’s largest privately held PBM, serving health plans, self-funded employers and government entities. Our business model is unique. We focus on effectively managing client pharmacy benefits to promote Lower Cost and Better Care through One Source. Our model aligns us with our clients. We help promote prescribing of lower-net-cost, medically...
MedImpact Healthcare Systems's Top Stability & Growth Strengths
Strong Market Position & Advantage: MedImpact is described as the largest independent PBM and a top‑five/six national player by share, with URAC PBM accreditation signaling operational maturity. Its national footprint includes more than 20 million members and over $40B in annual pharmacy transactions, indicating meaningful scale outside the Big Three.
Market Expansion: Recent acquisitions (Elixir in 2024 and Sav‑Rx in 2026) and a new New York City office reflect active expansion of scale and geography. Public‑sector wins and client transitions (e.g., Maryland go‑live in 2025) further point to a growing footprint.
Diversified Revenue Streams: Acquisitions of captive/stop‑loss firms in March 2026 broaden employer‑focused risk offerings beyond core PBM services. Expansion into labor‑focused PBM and specialty/mail capabilities adds additional sources of revenue.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and...
Catalent, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyses consistently place Catalent among the top global CDMOs, with meaningful presence in outsourced finished‑dose approvals and a broad end‑to‑end network. Its scale across oral, sterile, biologics, and cell & gene therapy supports late‑stage and commercial programs globally.
Investor Backing & Capital Strength: Novo Holdings’ completed acquisition provides deep‑capital sponsorship and strategic validation, with U.S./EU clearance reinforcing the platform’s importance. Related transactions around sterile sites highlight the strategic value of capabilities aligned to high‑demand medicines.
Future-Ready Strategy: Private ownership and a refreshed operating model aim to focus investment on biologics, cell & gene therapy, and clinical supply. GLP‑1–linked demand signals and capacity plans into the coming years indicate preparedness for sustained growth.
Rancho BioSciences is an international fee for service data curation company with analysis and developer services. Our customers include Pharma, Foundations, Government and Biotech. We have a team of experienced PhD and PhD/MD scientists around the world that deliver high quality work based on their expertise and domain knowledge in biology, diseases and clinical data. Rancho BioSciences is flexible and cost...
Millennium Health is an accredited specialty laboratory with over a decade of experience delivering timely, accurate, clinically-actionable information through our nationwide medication monitoring and drug testing services. Drug testing is used by substance use disorder and pain management providers to obtain objective information about patients’ recent use of prescription medications and/or illicit drugs and helps monitor the effectiveness of treatment...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
ICON plc's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.
Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.
Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.
